ZEP-3
/ Shulov Institute for Science
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
September 13, 2023
Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=165 | Recruiting | Sponsor: Shulov Innovate for Science Ltd. 2012 | Trial completion date: Dec 2023 ➔ Feb 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2024
Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
February 10, 2023
Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=165 | Recruiting | Sponsor: Shulov Innovate for Science Ltd. 2012 | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023
Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
March 29, 2022
Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=165 | Recruiting | Sponsor: Shulov Innovate for Science Ltd. 2012 | Trial completion date: Dec 2021 ➔ Dec 2022 | Trial primary completion date: Dec 2021 ➔ Dec 2022
Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
March 19, 2021
Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis
(clinicaltrials.gov)
- P2; N=165; Recruiting; Sponsor: Shulov Innovate for Science Ltd. 2012; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Dec 2020 ➔ Dec 2021
Clinical • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
1 to 4
Of
4
Go to page
1